BRIEF-A: an executive function rating scale for adults

Short answer

The BRIEF-A (Behavior Rating Inventory of Executive Function, Adult Version) is a rating scale published by PAR for ages 18 to 90. You and someone who knows you rate everyday self-regulation and executive function. It is not specific to ADHD, it is sold only to qualified professionals, and PAR now recommends its newer edition, the BRIEF2A.

Start the free screener

Executive function is the umbrella term for the mental skills that help you plan, organize, start, stop, switch and keep track. ADHD often comes up in the same conversations, but the two are not the same thing. The BRIEF-A was designed to describe executive function in everyday life, whatever the reason for difficulty.

The basics, from the publisher

Full name
Behavior Rating Inventory of Executive Function, Adult Version
Authors
Robert M. Roth, Peter K. Isquith and Gerard A. Gioia
Publisher
PAR, Inc.
Ages
18 to 90
Forms
Self-report and informant report
Purchase
Qualified professionals only (PAR qualification level B)
Current edition
PAR recommends the newer BRIEF2A

Why a rating of daily life, not a puzzle

Some executive function measures are tasks done in a testing room. The BRIEF-A instead asks about real routines: what happens at home, at work, with plans and with belongings. That makes it a window onto ordinary days. The tradeoff is that it reflects perception, yours and the informant's, rather than performance on a timed task.

Where it fits

Because executive function difficulties can come from many sources, a high rating does not point to ADHD in particular. A clinician reads it alongside history, interview and other measures.

That is also why the informant form matters. Your own sense of how organized you are can shift with mood and stress. A second rater who sees your routines adds a steadier reference point, and the differences between the two views can be as informative as the ratings themselves.

If PAR's newer BRIEF2A is used instead, the same broad idea applies: everyday executive function described by you and an informant, interpreted by a professional, and read as one part of a wider assessment

How it differs from what ADHDFalcon offers

Our free screener has two parts. Part 1 is the official six-question ASRS v1.1 Screener, which asks about ADHD-related experiences over the past six months. Part 2 is the ADHDFalcon Attention Profile, an original, non-clinical self-reflection with 24 statements across six everyday areas. It is scored 0 to 100 per area for description only, has no norms, and is not an ADHD measure; its full scores appear in the optional paid report.

The BRIEF-A is a licensed, standardized professional instrument with an informant form, scored against reference data by a clinician. Our Attention Profile is none of those things. It is a way to reflect on your own week, not a substitute for a professional rating scale, and we do not compare the two in quality.

What it does not do

It does not diagnose ADHD or any other condition, and it does not explain why executive function is hard for you. It is also not meant to be self-administered from an unofficial copy; PAR restricts purchase to qualified users who can interpret it.

The 6-question Adult Self-Report Scale-Version1.1 (ASRS-V1.1) Screener is a subset of the 18-question Adult ADHD Self-Report Scale-Version1.1 (Adult ASRSV1.1) Symptom Checklist.

© New York University and the President and Fellows of Harvard College.

Frequently asked questions

Is the BRIEF-A an ADHD test?

No. It rates executive function and self-regulation in everyday life. It may be used in ADHD evaluations, but difficulties it describes can have many causes.

Has the BRIEF-A been replaced?

PAR still lists the BRIEF-A but recommends the newer edition, the BRIEF2A.

Can I buy the BRIEF-A myself?

PAR sells it to professionals who meet its qualification level. A clinician administers and interprets it.

Sources

Source check: 2026-10-28. No medical review has occurred.

Published 2026-10-28. Factual source check: ADHDFalcon editorial team, factual source check, 2026-10-28. No medical review has occurred.